Avidity Touts Functional Improvements for DMD Therapy, Clearing Way to FDA on September 11, 2025 Approved Avidity Biosciences Blackfoot language Breakthrough Therapy Clinical Trials Functional improvements Muscular Dystrophy, Duchenne skipping submission United States Food and Drug Administration +
Wave Life Sciences' WVE-N531 Shows Promise in Duchenne Muscular Dystrophy Treatment on March 27, 2025 Approved Duchenne Dystrophin Gene Expression Health Improvement Muscle Tissue Muscular Dystrophy Phase 2 Clinical Trials skipping United States Food and Drug Administration WVE-N531 +
Avidity's Del-zota Shows Promise in Duchenne Muscular Dystrophy Treatment on March 18, 2025 Creatine Kinase Del-zota DMD Duchenne Dystrophin exon Muscular Dystrophy production RNA safety profile skipping +
FDA Lifts Clinical Hold on Entrada's Duchenne Muscular Dystrophy Drug ENTR-601-44 After Two Years on February 24, 2025 Duchenne ELEVATE-44 ENTR-601 Entrada exon Muscular Dystrophy Phase 1b trial skipping Study on Hold United States Food and Drug Administration +